Linked Life Data

16647250

Source:http://linkedlifedata.com/resource/pubmed/id/16647250

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-6-19
pubmed:abstractText
There is substantial evidence that a bioenergetic defect may play a role in the pathogenesis of Huntington's Disease (HD). A potential therapy for remediating defective energy metabolism is the mitochondrial cofactor, coenzyme Q10 (CoQ10). We have reported that CoQ10 is neuroprotective in the R6/2 transgenic mouse model of HD. Based upon the encouraging results of the CARE-HD trial and recent evidence that high-dose CoQ10 slows the progressive functional decline in Parkinson's disease, we performed a dose ranging study administering high levels of CoQ10 from two commercial sources in R6/2 mice to determine enhanced efficacy. High dose CoQ10 significantly extended survival in R6/2 mice, the degree of which was dose- and source-dependent. CoQ10 resulted in a marked improvement in motor performance and grip strength, with a reduction in weight loss, brain atrophy, and huntingtin inclusions in treated R6/2 mice. Brain levels of CoQ10 and CoQ9 were significantly lower in R6/2 mice, in comparison to wild type littermate control mice. Oral administration of CoQ10 elevated CoQ10 plasma levels and significantly increased brain levels of CoQ9, CoQ10, and ATP in R6/2 mice, while reducing 8-hydroxy-2-deoxyguanosine concentrations, a marker of oxidative damage. We demonstrate that high-dose administration of CoQ10 exerts a greater therapeutic benefit in a dose dependent manner in R6/2 mice than previously reported and suggest that clinical trials using high dose CoQ10 in HD patients are warranted.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0006-3002
pubmed:author
pubmed:issnType
Print
pubmed:volume
1762
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
616-26
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16647250-Adenosine Triphosphate, pubmed-meshheading:16647250-Animals, pubmed-meshheading:16647250-Body Weight, pubmed-meshheading:16647250-Coenzymes, pubmed-meshheading:16647250-Deoxyguanosine, pubmed-meshheading:16647250-Disease Models, Animal, pubmed-meshheading:16647250-Dose-Response Relationship, Drug, pubmed-meshheading:16647250-Huntington Disease, pubmed-meshheading:16647250-Male, pubmed-meshheading:16647250-Mice, pubmed-meshheading:16647250-Mice, Transgenic, pubmed-meshheading:16647250-Neostriatum, pubmed-meshheading:16647250-Nerve Tissue Proteins, pubmed-meshheading:16647250-Neuroprotective Agents, pubmed-meshheading:16647250-Nuclear Proteins, pubmed-meshheading:16647250-Rotarod Performance Test, pubmed-meshheading:16647250-Treatment Outcome, pubmed-meshheading:16647250-Ubiquinone
pubmed:year
2006
pubmed:articleTitle
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
pubmed:affiliation
Geriatric Research Education and Clinical Center, Bedford VA Medical Center, Bedford 01730, and Neurology Department, Boston University School of Medicine, MA 02180, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural